Biocon has reported a strong Q1 FY27 performance, with net profit rising more than four times year-on-year to ₹141 crore, compared with ₹31 crore in the year-ago quarter. Total income increased around 9% YoY to ₹4,391 crore. The key growth driver was the biopharma business, which grew 17% to ₹3,615 crore. Biosimilars revenue rose 16% to ₹2,855 crore, while generics increased 21% to ₹760 crore, supported by recently launched products, particularly in North America. 📌 StockYard Insight: Strong biosimilars growth and improving contribution from recently launched products could strengthen Biocon's earnings trajectory and reinforce its position in the global biopharma market. #Biocon #PharmaStocks #Biosimilars #Healthcare #Biopharma #StockYardResearch

#TechnicalViews#StockInNews#EquityResearch#PersonalFinance#SectorBreakouts

579 likes·27 comments